Allogene Therapeutics Inc
Research Allogene Therapeutics Inc (ALLO) on Bullrun: market cap USD 766.24M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALLO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 766.24M
- Financial periodFY2025
- Revenue growth-100.0%
- Net income-USD 190.89M
- Free cash flow-USD 149.63M
Valuation Snapshot
latest market cap is USD 766.24M.
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
Frequently asked questions
What is Allogene Therapeutics Inc's market cap?
Allogene Therapeutics Inc's market capitalization is USD 766.24M.
What does Allogene Therapeutics Inc do?
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.